Compass Pathways Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
27.7%projected annual EPS growth
Analyst Coverage
16analysts covering
FY EPS (est.)
-$1.43next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Final NDA Submission for COMP360 in TRD | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
COMP006 Part B 26-week Durability Data QuarterlyTarget: Statistically significant durability of response at 26 weeks
NDA Submission Progress QuarterlyTarget: Complete final NDA submission by Q4 2026
Cash and Cash Equivalents Quarterly466MTarget: Maintain sufficient runway beyond launch and into 2028
Watch Items
- COMP006 Part B 26-week durability data readoutTrigger: Failure to show durable efficacy at 26 weeks or unexpected safety signalsAction: Re-evaluate clinical development timeline and commercial viability of COMP360
- FDA NDA Review Timeline under CNPVTrigger: Delay in FDA acceptance of rolling NDA or extended review beyond 1-2 months post-filingAction: Engage with regulatory consultants and adjust commercial launch readiness plans
- Federal and State Rescheduling of PsilocybinTrigger: Failure of DEA to reschedule psilocybin within expected timelines post-FDA approvalAction: Lobby regulatory bodies and coordinate with industry coalitions to accelerate rescheduling
Research as of 19 Jun 2026